... français ou étrangers, des laboratoires publics ou privés.ANGELO BATTELLI.-Sol fenomeno Peltier à diverse température e sulle ...
Tópico(s): Nonlinear Dynamics and Pattern Formation
1890 - Société Française de Physique | Journal de Physique Théorique et Appliquée
Tópico(s): History and advancements in chemistry
1893 - Italian Physical Society | Il Nuovo Cimento
Tópico(s): Historical and Environmental Studies
1893 - Société Française de Physique | Journal de Physique Théorique et Appliquée
Tópico(s): Ancient Mediterranean Archaeology and History
1890 - Italian Physical Society | Il Nuovo Cimento
Tópico(s): Historical and Environmental Studies
1890 - Italian Physical Society | Il Nuovo Cimento
Tópico(s): Historical and Environmental Studies
1892 - Italian Physical Society | Il Nuovo Cimento
Tópico(s): History and advancements in chemistry
1892 - Italian Physical Society | Il Nuovo Cimento
est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Tópico(s): Catalysis and Oxidation Reactions
1891 - Société Française de Physique | Journal de Physique Théorique et Appliquée
Tópico(s): Educational and Social Studies
1891 - Italian Physical Society | Il Nuovo Cimento
Tópico(s): Nonlinear Dynamics and Pattern Formation
1891 - Société Française de Physique | Journal de Physique Théorique et Appliquée
Tópico(s): Nonlinear Dynamics and Pattern Formation
1895 - Italian Physical Society | Il Nuovo Cimento
Tópico(s): Management, Economics, and Public Policy
1917 - Italian Physical Society | Il Nuovo Cimento
Pier Luigi Tazzari, Maria Giulia Battelli, Ada Abbondanza, Angelo Dinota, Simonetta Rizzi, Marco Gobbi, Fiorenzo Stirpe,
We report on the preparation of an antibody-conjugated enzyme consisting of xanthine oxidase, a free-radical-producing enzyme, linked to the 62B1 monoclonal antibody, which recognizes the last steps of differentiation of B cell lineage (plasma cell and hairy cells). The conjugate specifically kills target cells, retaining both enzymic and immunological properties, without any damage to normal myeloid clonogenic efficiency. The model is suitable for ex vivo bone marrow purging in multiple myeloma ...
Tópico(s): Hematopoietic Stem Cell Transplantation
1989 - Wolters Kluwer | Transplantation
Mariella Chiricolo, Pier Luigi Tazzari, Ada Abbondanza, Angelo Dinota, Maria Giulia Battelli,
Toxicity to Raji cells of the xanthine oxidase/hypoxanthine system is related to the formation of single‐strand DNA breaks. DNA damage was proportional to the concentration of xanthine oxidase and to the time of exposure. It was prevented by the absence of hypoxanthine, or by the presence of allopurinol, or both superoxide dismutase and catalase. The release of 51 Cr from damaged cells was detectable 12h after the inhibition of cloning efficiency and the production of DNA breakage. These data suggest ...
Tópico(s): Neonatal Health and Biochemistry
1991 - Wiley | FEBS Letters
Matteo Santoni, Francesco Massari, Francesco Piva, Francesco Carrozza, Vincenzo Di Nunno, Alessia Cimadamore, Angelo Martignetti, Rodolfo Montironi, Nicola Battelli,
Renal cell carcinoma (RCC) represents a heterogeneous group of cancers with distinct histological features, molecular alterations, prognosis, and response to therapy. Target agents directed against vascular endothelial growth factor and its receptor and mammalian target of rapamycin (mTOR) inhibitors have completely changed the landscape of RCC. However, the rate of complete response is still low, thus supporting the research of novel therapeutic agents. Area covered: The authors describe the chemical ...
Tópico(s): Cancer Genomics and Diagnostics
2018 - Taylor & Francis | Expert Opinion on Pharmacotherapy
Matteo Santoni, Alessia Cimadamore, Francesco Massari, Francesco Piva, Gaetano Aurilio, Angelo Martignetti, Marina Scarpelli, Vincenzo Di Nunno, Lidia Gatto, Nicola Battelli, Liang Cheng, Antonio López-Beltrán, Rodolfo Montironi,
Background: In human populations, a certain amount of data correlate obesity/body mass index (BMI) with urothelial cancer (UC) and prostate cancer (PCa) occurrence, however this is not fully elucidated at all stages of disease. In an attempt to shed light on uncertain areas in such field, in the present review we illustrate the main molecular mechanisms linking obesity and cancer, focusing on the correlation between obesity and tumor risk, disease progression and response to chemo- and immunotherapy ...
Tópico(s): Prostate Cancer Treatment and Research
2019 - Multidisciplinary Digital Publishing Institute | Cancers
Matteo Santoni, Francesco Massari, Sergio Bracarda, Enrique Grande, Marc Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Javier Molina‐Cerrillo, Veronica Mollica, Alessandro Rizzo, Nicola Battelli,
A subset of patients with metastatic renal cell carcinoma (mRCC), deemed as primary refractory, shows progressive disease as the best response to first-line therapy even when treated with novel immune-based combos.We aimed to assess the outcome of patients treated with second-line cabozantinib for mRCC primary refractory to first-line therapy defined as Response Evaluation Criteria in Solid Tumors (RECIST) progression in the computed tomography scan as the best response to the upfront treatment.We ...
Tópico(s): Bladder and Urothelial Cancer Treatments
2022 - Elsevier BV | European Urology Focus
Tópico(s): Management, Economics, and Public Policy
1917 - Italian Physical Society | Il Nuovo Cimento
Marta Pestrin, Silvia Bessi, Fabio Puglisi, Alessandro Marco Minisini, Giovanna Masci, Nicola Battelli, Alberto Ravaioli, Luca Gianni, R. Di Marsico, Carlo Tondini, Stefania Gori, R. Charles Coombes, Justin Stebbing, Laura Biganzoli, Marc Buyse, Angelo Di Leo,
Tópico(s): Advanced Breast Cancer Therapies
2012 - Springer Science+Business Media | Breast Cancer Research and Treatment
Matteo Santoni, Francesco Massari, Marc Matrana, Umberto Basso, Ugo De Giorgi, Gaetano Aurilio, Sebastiano Buti, Lorena Incorvaia, Mimma Rizzo, Angelo Martignetti, Diana Maslov, Karine Tawagi, Ernest Philon, Zoë Blake, Camillo Porta, Nicola Battelli,
Statins are widely used in an ageing population, including subjects with solid malignancies. However, no conclusive evidence is currently available on their potential influence on patients' outcome. We aimed to assess whether statin exposure affects the survival of patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.Medical records of patients with documented mRCC treated with second- or third-line nivolumab were reviewed at ten institutions from Italy, Spain and the USA. ...
Tópico(s): Ferroptosis and cancer prognosis
2022 - Elsevier BV | European Journal of Cancer
... includes four studies of Lercaro, by Giuseppe Alberigo, Angelo Varni, Alberto Melloni, and Giuseppe Battelli. Although Giacomo Lercaro is best remembered for his ...
Tópico(s): Historical and Environmental Studies
2006 - The Catholic University of America Press | The Catholic historical review
Angelo Angelo, Federico Battelli, D. Mazzotto,
Tópico(s): Historical and Environmental Studies
1899 - Italian Physical Society | Il Nuovo Cimento
Matteo Santoni, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michèle Milella, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Mimma Rizzo, Giacomo Cartenì, Enrique Grande, Marc Matrana, Simon J. Crabb, Nuno Vau, Giulia Sorgentoni, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli,
We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan–Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- ( ...
Tópico(s): Multiple and Secondary Primary Cancers
2021 - Multidisciplinary Digital Publishing Institute | Diagnostics
Matteo Santoni, Gaetano Aurilio, Francesco Massari, Enrique Grande, Marc Matrana, Mimma Rizzo, Ugo De Giorgi, Lorena Incorvaia, Angelo Martignetti, Javier Molina‐Cerrillo, Ignacio Ortego Zabalza, Veronica Mollica, Alessandro Rizzo, Nicola Battelli, Camillo Porta,
Tyrosine-kinase inhibitors (TKIs) still represent a first-line option for selected patients with metastatic Renal Cell Carcinoma (mRCC). We aimed to compare the real-world efficacy of nivolumab or cabozantinib as second-line therapy in specific mRCC subpopulations.We retrospectively collected data from 11 centers from Italy, Spain and US. Overall Survival (OS) and Progression-Free Survival (PFS) were analyzed using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate ...
Tópico(s): Cancer Genomics and Diagnostics
2022 - Elsevier BV | Clinical Genitourinary Cancer
Giulio Francolini, Vanessa Di Cataldo, Pietro Garlatti, Saverio Caini, Alessio Bruni, Nicola Simoni, Matteo Augugliaro, Roberto Iacovelli, Luca Tagliaferri, Nicola Battelli, Gianluca Ingrosso, Angelo Porreca, Marco Trovò, Giuseppe Fornarini, Giuseppe Carlo Iorio, Alessia Guarneri, Michele Sisani, Lorenzo Antonuzzo, Alfio Di Grazia, Lorenzo Livi,
Tópico(s): Medical Imaging Techniques and Applications
2025 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Nicola Battelli, Cristian Massacesi, Chiara Braconi, Alberta Pilone, Luigi Manzione, Angelo Dinota, S. Cobelli, A. Scanni, F. Sturba, Giusi Giacomini, Donatella Morale, Francesca Giorgi, Diego Tummarello, Stefano Cascinu,
Objective: The aim of this study was to evaluate the feasibility of a combination of epirubicin and paclitaxel followed by intravenous (iv) cyclophosphamide, methotrexate, and 5-fluorouracile (CMF) as adjuvant treatment of breast cancer patients with 10 or more metastatic axillary lymph nodes. Methods: Forty-four patients entered this multicenter study and received 4 cycles of epirubicin (E 120 mg/m2 day 1, q3 weeks) and paclitaxel (T 135 mg/m2 day 1, q3 weeks), followed by 4 cycles of iv CMF (days 1 ...
Tópico(s): HER2/EGFR in Cancer Research
2006 - Lippincott Williams & Wilkins | American Journal of Clinical Oncology
Franco Molina, E. Armando, Roberto Balia, O. Battelli, E. Bozzo, G. Budetta, G. Caneva, Marcello Ciminale, N. De Florentiis, Angelo De Santis, G. Dominici, M. Donnaloia, A. Elena, V. Iliceto, R. Lanza, M. Loddo, A. Meloni, E. Pinna, Giovanni Santarato, R. Zambrano,
Tópico(s): Geophysics and Gravity Measurements
1985 - Copernicus Publications | Annales Geophysicae
Produção Nacional
Revisado por pares
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, Y. Okada, Francesco Massari, Geòrgia Anguera, Michele Dionese, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin Myint, Luca Galli, Vinícius Carrera Souza, Renate Pichler, Ugo De Giorgi, María Natalia Gandur Quiroga, Danielle Gilbert, Lazar Popović, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J. Crabb, Javier Molina‐Cerrillo, Marcelo Freitas, Murilo Luz, Roberto Iacovelli, Fabio Calabrò, Deniz Tural, Francesco Atzori, Zsófia Kürönya, Rita Chiari, Saul Campos‐Gómez, Orazio Caffo, André P. Fay, Jakub Kucharz, Paolo Andrea Zucali, José Augusto Rinck, Annalisa Zeppellini, Diogo Assed Bastos, Gaetano Aurilio, Augusto Mota, Karine Martins da Trindade, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Nuno Vau, Patrizia Giannatempo, Allan Barillas, Fernando Sabino Marques Monteiro, Breno Dauster, Carlo Cattrini, Lucas Nogueira, Roni de Carvalho Fernandes, Emmanuel Seront, Luis García Aceituno, Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernández, Maria Bassanelli, Giandomenico Roviello, Halima Abahssain, Giuseppe Procopio, Michèle Milella, Jindřich Kopecký, Angelo Martignetti, Carlo Messina, Manuel Caitano, Eva Inman, Ravindran Kanesvaran, Daniel Herchenhorn, Daniele Santini, Ray Manneh Kopp, Renato Bisonni, Roubini Zakopoulou, Alessandra Mosca, Francesco Morelli, Fernando Cotait Maluf, Andrey Soares, Fernando Furlan Nunes, Álvaro Pinto, Anca Zgură, Lorena Incorvaia, Jawaher Ansari, Ignacio Ortego Zabalza, Johannes Landmesser, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Nicola Battelli, Camillo Porta, Joaquim Bellmunt, Matteo Santoni,
Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab. We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries. ...
Tópico(s): Urinary and Genital Oncology Studies
2023 - Springer Science+Business Media | Cancer Immunology Immunotherapy
Matteo Santoni, Daniel Y.C. Heng, Sergio Bracarda, Giuseppe Procopio, Michèle Milella, Camillo Porta, Marc Matrana, Giacomo Cartenì, Simon J. Crabb, Ugo De Giorgi, Umberto Basso, Cristina Masini, Fabio Calabrò, Maria Giuseppa Vitale, Daniele Santini, Francesco Massari, Luca Galli, Giuseppe Fornarini, Riccardo Ricotta, Sebastiano Buti, Paolo Andrea Zucali, Orazio Caffo, Franco Morelli, Francesco Carrozza, Angelo Martignetti, Alain Gelibter, Roberto Iacovelli, Alessandra Mosca, Francesco Atzori, Nuno Vau, Lorena Incorvaia, Cinzia Ortega, Marina Scarpelli, Antonio López-Beltrán, Liang Cheng, Vittorio Paolucci, Jeffrey Graham, Erin Pierce, Sarah Scagliarini, Pierangela Sepe, Elena Verzoni, Sara Merler, Mimma Rizzo, Giulia Sorgentoni, Alessandro Conti, Francesco Piva, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli,
Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy for ...
Tópico(s): Cancer Genomics and Diagnostics
2019 - Multidisciplinary Digital Publishing Institute | Cancers